At EURETINA 2023, Samsung Bioepis shared positive comparative efficacy data on its aflibercept biosimilar candidate, demonstrating that the product is as safe and effective as the originator (Eylea).
New data from a phase 3 comparative efficacy study showed that SB15, an aflibercept biosimilar candidate, was as safe and effective as its reference product (Eylea) in patients with neovascular age-related macular degeneration (nAMD).
The results were presented at EURETINA 2023, the annual meeting of the European Retina, Macula and Vitreous Society. The conference was held October 5-8 in Amsterdam, the Netherlands.
“We are pleased to present the switching data of SB15 from reference aflibercept that continues to demonstrate its comparable clinical efficacy and safety in treating patients with nAMD. We hope the study results also help allay concerns over safety and efficacy of biosimilars for their use in patients who were previously treated with reference product,” said HyeJin Kim, vice president and medical and lifecycle safety team leader at Samsung Bioepis.
The news comes after the European Medicines Agency granted Europe’s first aflibercept biosimilar (Yesafili; Biocon Biologics) marketing authorization.
Aflibercept is a vascular endothelial growth factor (VEGF) receptor inhibitor that is administered intravitreally. This medication class is used to treat macular edema and myopic choroidal neovascularization. When treating eye conditions, anti-VEGF medicines stop the abnormal blood vessels leaking, growing, and bleeding under the retina, which can cause intense pain and vision loss for patients.
The phase 3 study was a randomized, double-masked, parallel-group, multicenter assessment that included 449 participants. The patients were randomized 1:1 to receive 3 monthly injections (2 mg) of SB15 or the reference product, followed by treatment once every 8 weeks up to week 48.
The primary outcome was change from baseline in best corrected visual acuity (BVCA) at week 8. All end points were followed through week 56, and the safety and efficacy after transitioning products was comparable with that of prior to transitioning.
The mean BVCA between the switching and the reference product groups was 65.3 at week 32 (prior to switching) and 65.8 at week 56 (post switching) vs 65.2 at week 32 and 65.8 at week 56, respectively.
A post-hoc analysis was conducted to assess the biosimilarity of the 2 products. The analysis demonstrated that switching from Eylea to SB15 was safe and did not compromise patients’ clinical outcomes in nAMD.
Samsung Bioepis is developing SB15 in partnership with Biogen as part of a 2019 commercialization agreement. The partnership also includes SB11 (Byooviz), a ranibizumab biosimilar.
“This post hoc analysis provides valuable insights on the outcomes of switches from the reference biologic to SB15 and may help clinicians to make well-informed decisions on potential use of SB15 if approved”, said Mourad Farouk Rezk, MD, MBA, vice president and head of global medical and development, Biogen Biosimilars Unit.
Reference
Samsung Bioepis presents post-hoc analysis of phase 3 clinical trial for SB15, a proposed biosimilar to Eylea (aflibercept), at EURETINA 2023. News release. Samsung Bioepis. October 7, 2023. Accessed October 9, 2023. https://www.samsungbioepis.com/en/newsroom/newsroomView.do?idx=352¤tPage=1
Data Show Promise for Adalimumab Biosimilars to Deliver on Safety, Cost Savings
May 16th 2024Two posters from the Academy of Managed Care Pharmacy’s annual meeting provided hope that despite low uptake so far, adalimumab biosimilars can deliver on the promise of comparable safety and efficacy with the originator in multiple disease states as well as cost savings.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Partnering for Biosimilar Security: India's Role in US Health Care Savings, Supply Chain Stability
May 9th 2024As Indian pharmaceutical companies supplied 4 of every 10 prescriptions in the US in 2022, generating $1.3 trillion in health care savings, a new IQVIA report highlights concerns about supply chain risks and advocates for partnerships to bolster biosimilar security and overall supply chain resilience.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
Dr Sophia Humphreys Provides Calls to Action to Ensure Biosimilar Market Sustainability
April 30th 2024During her presentation during Festival of Biologics USA, Sophia Humphreys, PharmD, director of formulary management at Sutter Health, gave an overview of current challenges and opportunities for the biosimilar market and offered calls to action for multiple stakeholders.